trade fundament data
upsid target
click enter text
ep guidanc maintain rev trim
report financi result friday market
open beat revenu ep covid tailwind compani
maintain ep guidanc trim total revenu guidanc slightli
said pend acquisit remain track gave color
think impact covid product like botox
qualit deal still schedul close may like
first-tim pro-forma guidanc wont given result juli
new stand-alon model revenu estim rise
averag ep rise averag new pt
vs unchang pro-forma abbv agn
bodi report full analysi
inform us/eu pharma stock cover
see march issu monthli controversi
pipelin unplug confer call may
vice chairman presid dr severino estimate regist click
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
friday open
report result beat revenu ep
lower revenu guidanc slightli maintain stand-alone ep guidanc
said everyth remain track pend acquisit allergan even though covid
clear impact certain product line like botox
saw share price rise outperform peer group broader market
overal perspect like mani larg cap biopharma name cover report strong
result covid provid partial boost compani reiter ep guidanc trim revenu growth
guidanc compani cover case lower ep
compani provid revenu guidanc one driver like abbv heavi depend humira
covid caus advers payer mix shift medicaid past larg price increas
year net price channel substanti lower channel skyrizi rinvoq continu
well sinc launch skyrizi guidanc increas pipelin new
news import one emerg product predict get airtim later year abbv
tnf/steroid ra first-in-human data releas later manag spent
lot time discuss pend acquisit say transact track say long-term valu
still gave benchmark recoveri franchis aesthet botox
other could look like gener gave assur deal still slate close may
pro-forma guidanc probabl come result juli best guess keep investor
wonder fold abbv outlook better slowli head major loe
form us humira model abbv agn good growth
meaning step ep flattish growth anoth sizeabl
step imbruvica loe trajectori suggest even lie ahead
year long-term ep trajectori explain price-to-earnings multipl substanti lower
peer group averag low valuat context low event risk partli
combin pipelin quit thin higher-than-averag dividend yield current suggest
downsid limit question remain drive price-to-earnings multipl expans higher catalyst
still long-term growth issu rate peer perform posit bia valu perspect
note recent month
pipelin unplug confer call may vice chairman presid dr
severino estimate regist click
inform see global pharmaceut march issu monthli controversi
revenu report sale vs consensu
ep report non-gaap ep vs consensu
page
humira sale vs consensu skyrizi sale vs
consensu continu rapid ramp sinc launch rinvoq sale vs consensu
imbruvica sale vs consensu
hcv sale vs consensu
guidanc stand-alon deal closur exhibit
revenu lower prior guidanc growth
ep maintain
stand-alon revenu essenti unchang
revenu stand-alon estim increas
stand-alon ep estim increas depend year
ep compound-annual-growth-rate pro-forma ep compound-annual-growth-rate increas slightli vs prior
well peer averag growth peer average compound-annual-growth-rate
price set use pro-forma estim decreas vs prior
repres unchang multipl new pro-forma ep estim impli price-to-earnings
stand-alon ep estim updat agn pro-forma estim see exhibit
report
adjust covid boost underli sale growth ep boost covid
start return normal oper certain geographi covid two fundament impact
busi first variabl impact new patient start mani derm offic new patient start lower
normal second lower hospit use product venclexta modest
increas patient assist program shift payer mix maintain ep guidanc aesthet
rev profit impact differ vs botox therapeut may
impact botox aesthet aesthet see impact suggest quick rebound
remain confid impact transient op margin boost covid guidanc stand-
alon look total revenu growth vs fx neg impact fy
us humira growth vs skyrizi global sale global hcv
approach prior op margin prior
page
improv vs prior guidanc element unchang rev assum
revers covid fx impact op margin ep debt paydown end net
debt ebidta end
 dividend chang view growth expect go forward vs pre-covid
say chang underli assumpt dividend growth disclos
 help fill humira hole view lie ahead like
resum bolt acquisit singl digit billion dollar transact soon current
year gener describ chang capit alloc plan bd team
still activ aggress pursu good opportun time continu deal
focu oncolog ta
 talk past de-lever commit say everyth track note
paid end may
ftc final stage review process still expect closur may flow sustain dividend allow
 view valu deal chang due covid see chang
long-term valu deal aesthet import busi investor ask long
recov reason question ask continu assess saw v-
shape recoveri agn busi china also provid data point reopen week
show modestli lower activ pre-covid variou metric demand return term
aesthet competitor remind less well capit vs
 report result say need ask
 covid impact integr plan done integr work alreadi well
prepar sever month alreadi doesnt believ impact realli synergi
plan place
 pro-forma guidanc provid deal closur provid sometim
close could come doesnt know sure
outlin variou initi test therapeut kaletra studi on-going result soon
also studi imbruvica start delay noth materi import timelin
 digit market differ vs peer reflect skyrizi rinvoq
number cant realli say differ vs competitor doesnt think drive skyrizi
rinvoq perform
page
 view second wave covid anticip anoth shelter-in-plac
situat fall
humira y/i biosimilar dynam consist expect covid stock
 lower humira us guidanc due payer mix chang switch therapi someth
els say reflect channel mix shift medicaid primari driver impact
lower new patient start
 covid impact rate uptak biosimilar eu humira eros bit better
expect cant tell whether due covid need time elaps know sure
skyrizi captur in-play pso share rinvoq in-play ra patient share rinvoq atop derm data
track discontinu ra jak/btk indic continu studi would
taken skyrizi guidanc higher covid
 skyrizi rinvoq talk long-term estim previous provid say
chang remain impress speed ramp rinvoq acceler similar skyrizi
becom jak space within month
 differ rate uptak skyrizi rinvoq among privat practic doc vs salari
physician say know answer question realli suggest
 like jade compar trial run head head rinvoq vs dupix
atop derm investor view result underwhelm expect someth differ
trial well awar result say need look drug program separ
feel good pk coverag rinvoq ad strong result look forward result
 skyrizi rinvoq much growth come back humira posit market
say success depend product profil also good access
steroid/tnf ra first human result year
 want see describ still proof concept studi want
see efficaci greater therapi higher level respons good safeti includ less steroid effect
pituitari axi phase result healthi volunt believ deliv drug without steroid
side effect expect ra patient
page
mavyret impact due covid also competition/pric
page
exhibit show compani report actual result vs estim consensu
exhibit abbvi result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit abbvi guidanc vs wr estim old new
page
oldnewoldnewtot op growth op growth interest tax guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement agn incom statement product revenu
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper revenu earli phase total
exhibit wr balanc sheet cash flow statement
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang short-term issuanc lt lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock held paid-in comprhens sharehold liabil sharehold
